Development of a LC-MS/MS method to analyze 5-methoxy-N,N- dimethyltryptamine and bufotenine: Application to pharmacokinetic study

Bioanalysis

Volumn 1, Issue 1, 2009, Pages 87-95

  Shen, Hong Wu ^a   Jiang, Xi Ling ^a   Yu, Ai Ming ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952291461     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.7     Document Type: Article

References (25)

1. Yu AM. Indolealkylamines: biotransformations and potential drug-drug interactions. AAPS J 10(2), 242-253 (2008).
2. Brush DE, Bird SB, Boyer EW. Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances. J. Toxicol. Clin. Toxicol. 42(2), 191-195 (2004).
3. Long H, Nelson LS, Hoffman RS. a-methyltryptamine revisited via easy Internet access. Vet. Hum. Toxicol. 45(3), 149 (2003).
4. Muller AA. New drugs of abuse update: foxy methoxy. J. Emerg. Nurs. 30(5), 507-508 (2004).
5. Alatrash G, Majhail NS, Pile JC. Rhabdomyolysis after ingestion of "foxy, " a hallucinogenic tryptamine derivative. Mayo Clin. Proc. 81(4), 550-551 (2006).
6. Sklerov J, Levine B, Moore KA, King T, Fowler D. A fatal intoxication following the ingestion of 5-methoxy-N, N-dimethyltryptamine in an ayahuasca preparation. J. Anal. Toxicol. 29(8), 838-841 (2005).
7. Ott J. Pharmanopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. J. Psychoactive Drugs 33(3), 273-281 (2001).
8. Ott J. Pharmepena-psychonautics: human intranasal, sublingual and oral pharmacology of 5-methoxy-N, N-dimethyl-tryptamine. J. Psychoactive Drugs 33(4), 403-407 (2001).
9. McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol. Ther. 102(2), 111-129 (2004).
10. Callaway JC, Grob CS, McKenna DJ et al. A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in an ayahuasca preparation. J. Anal. Toxicol. 30(6), 406-407; author reply 407 (2006).
11. 14C in the rat. Biochem. Pharmacol. 18(10), 2771-2781 (1969).
12. Yu AM, Idle JR, Herraiz T, Kupfer A, Gonzalez FJ. Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13(6), 307-319 (2003).
13. Yu AM, Idle JR, Gonzalez FJ. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab. Rev. 36(2), 243-277 (2004).
14. Roth BL, Choudhary MS, Khan N, Uluer AZ. High-affnity agonist binding is not suffcient for agonist effcacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modifed ternary complex model. J. Pharmacol. Exp. Ther. 280(2), 576-583 (1997).
15. McBride MC. Bufotenine: toward an understanding of possible psychoactive mechanisms. J. Psychoactive Drugs 32(3), 321-331 (2000).
16. Fuller RW, Snoddy HD, Perry KW. Tissue distribution, metabolism and effects of bufotenine administered to rats. Neuropharmacology 34(7), 799-804 (1995).
17. Karkkainen J, Forsstrom T, Tornaeus J et al. Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues. Scand. J. Clin. Lab. Invest. 65(3), 189-199 (2005).
18. Forsstrom T, Tuominen J, Karkkainen J. Determination of potentially hallucinogenic N-di methylated indoleamines in human urine by HPLC/ESI-MS-MS. Scand. J. Clin. Lab. Invest. 61(7), 547-556 (2001).
19. Barker SA, Littlefeld-Chabaud MA, David C. Distribution of the hallucinogens N, N-dimethyltryptamine and 5-methoxy-N, N-dimethyltryptamine in rat brain following intraperitoneal injection: application of a new solid-phase extraction LC-APcI-MS-MS-isotope dilution method. J. Chromatogr. B Biomed. Sci. Appl. 751(1), 37-47 (2001).
20. Chen BH, Liu JT, Chen WX, Chen HM, Lin CH. A general approach to the screening and confrmation of tryptamines and phenethylamines by mass spectral fragmentation. Talanta 74(4), 512-517 (2008).
21. Karkkainen J, Raisanen M, Huttunen MO et al. Urinary excretion of bufotenin (N, N-dimethyl-5-hydroxytryptamine) is increased in suspicious violent offenders: a confrmatory study. Psychiatry Res. 58 (2), 145-152 (1995).
22. Winter JC, Filipink RA, Timineri D, Helsley SE, Rabin RA. The paradox of 5-methoxy-N, N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors. Pharmacol. Biochem. Behav. 65(1), 75-82 (2000).
23. Krebs-Thomson K, Ruiz EM, Masten V, Buell M, Geyer MA. The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology (Berl.) 189(3), 319-329 (2006).
24. Yu AM, Haining RL. Expression, purifcation, and characterization of mouse CYP2d22. Drug Metab. Dispos. 34(7), 1167-1174 (2006).
25. Corchero J, Granvil CP, Akiyama TE et al. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4a on the disposition of debrisoquine in the mouse. Mol. Pharmacol. 60(6), 1260-1267 (2001).